PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19371952-4 2009 Both forskolin (a direct activator of adenylyl cyclase) and dibutyryl-cAMP (DBcAMP, a permeable analog of cAMP) suppressed production of TARC and MDC in parallel with the activation of NF-kappaB in IFN-gamma and TNF-alpha-stimulated HaCaT cells. Bucladesine 76-82 tumor necrosis factor Homo sapiens 212-221 21371514-5 2011 While GLT-1a and GLT-1b mRNAs were both increased in response to treatment with N(6),2"-O-dibutyryladenosine 3",5"-cyclic monophosphate (dBcAMP), the culture supplement G5 or tumor necrosis factor-alpha (TNF-alpha), the regulation of GLT-1b appeared quicker and was more pronounced. Bucladesine 80-135 tumor necrosis factor Homo sapiens 204-213 19371952-8 2009 Of note, the IFN-gamma plus TNF-alpha-stimulated activation of p38 MAPK was suppressed following incubation with forskolin or DBcAMP alone. Bucladesine 126-132 tumor necrosis factor Homo sapiens 28-37 16751174-7 2006 Enhancement of cellular cAMP with dibutyryl cAMP abrogated LPS-mediated TNF-alpha expression in ethanol-treated cells. Bucladesine 34-48 tumor necrosis factor Homo sapiens 72-81 14688373-8 2004 Inhibition of LPS internalization by cytochalasin D or treatment with dibutyryl cAMP attenuated ICAM-1 expression and TNF production by PBMC. Bucladesine 70-84 tumor necrosis factor Homo sapiens 118-121 15178710-4 2004 In contrast, dibutyryl-cyclic adenosine monophosphate blocked NO(.-)-induced production of TNF-alpha (P=0.009) but not IL-8. Bucladesine 13-53 tumor necrosis factor Homo sapiens 91-100 16822680-4 2006 In line with these, LPS (1 microgml(-1))- and TNF-alpha (200 ngml(-1))-induced DNA fragmentation, assessed by agarose gel electrophoresis, was significantly reduced by treatment with cilostazol (10 microM) as well as by dibutyryl cAMP (100 microM). Bucladesine 220-234 tumor necrosis factor Homo sapiens 46-55 15464057-3 2004 Similar results were obtained using the membrane-permeable cAMP analogue db-cAMP, which caused preferential inhibition of TNFalpha expression. Bucladesine 73-80 tumor necrosis factor Homo sapiens 122-130 12446019-3 2002 A mechanistic analysis revealed that the cAMP analog, dibutyryl cyclic AMP (dbcAMP), or the adenyl cyclase activator, forskolin, effectively suppressed the stimulant-induced TNF-alpha production by reducing the nuclear translocation and DNA binding activity of NF-kappaB. Bucladesine 54-74 tumor necrosis factor Homo sapiens 174-183 12606779-6 2003 The cell-permeable cAMP analog dibutyryl cAMP partially and almost simultaneously suppressed all of these CT105-induced signaling pathways through excessive CREB phosphorylation, which led to decreased CREB DNA binding activity and reduced TNF-alpha expression. Bucladesine 31-45 tumor necrosis factor Homo sapiens 240-249 12606779-7 2003 Furthermore, dibutyryl cAMP decreased the interaction of the p65 nuclear factor-kappa B with CREB binding protein, thus further inhibiting CT105-mediated TNF-alpha expression. Bucladesine 13-27 tumor necrosis factor Homo sapiens 154-163 12446019-3 2002 A mechanistic analysis revealed that the cAMP analog, dibutyryl cyclic AMP (dbcAMP), or the adenyl cyclase activator, forskolin, effectively suppressed the stimulant-induced TNF-alpha production by reducing the nuclear translocation and DNA binding activity of NF-kappaB. Bucladesine 76-82 tumor necrosis factor Homo sapiens 174-183 11469886-8 2001 RESULTS: cAMP-elevating agents inhibited LPS-stimulated TNF-alpha release (0.77 +/- 0.13 ng/10(6) cells in LPS + dbcAMP and 0.68 +/- 0.19 ng/10(6) cells in LPS + FSK, both P < 0.05 vs 1.61 +/- 0.34 ng/10(6) cells in LPS alone). Bucladesine 113-119 tumor necrosis factor Homo sapiens 56-65 12228279-7 2002 CT, LT, dibutyryl-cyclic-3",5"-AMP, and Forskolin also dominantly inhibit interleukin 12 and tumor necrosis factor alpha production by MDDC in the presence of saturating concentrations of lipopolysaccharide. Bucladesine 8-34 tumor necrosis factor Homo sapiens 74-120 11602691-2 2001 Addition of dibutyryl cAMP mimicked rolipram inhibitions on proliferation, IL-2, TNF-alpha, and IFN-gamma but not on IL-10 or IL-5 production. Bucladesine 12-26 tumor necrosis factor Homo sapiens 81-90 12101267-4 2002 The presence of a phosphodiesterase (PDE) inhibitor (IBMX) and cAMP analogs (8Br-cAMP, Db-cAMP) reversed the observed TNF-alpha effects. Bucladesine 87-94 tumor necrosis factor Homo sapiens 118-127 11193379-8 2000 TNF-alpha production was almost completely suppressed by dibutyryl cyclic AMP (dbcAMP), whereas IL-1 beta production appeared to be partially refractory even at the highest concentration examined. Bucladesine 57-77 tumor necrosis factor Homo sapiens 0-9 11310848-10 2001 Furthermore, the effect of TGF-beta or indomethacin on blockage of TNF-alpha-stimulated MMP-9 production was reversed by the addition of either exogenous PGE2 or the cyclic AMP (cAMP) analogue Bt2cAMP. Bucladesine 193-200 tumor necrosis factor Homo sapiens 67-76 11193379-8 2000 TNF-alpha production was almost completely suppressed by dibutyryl cyclic AMP (dbcAMP), whereas IL-1 beta production appeared to be partially refractory even at the highest concentration examined. Bucladesine 79-85 tumor necrosis factor Homo sapiens 0-9 10559188-6 1999 NO donors and H89, an inhibitor of cAMP-dependent protein kinase increased, while dibutyryl cAMP (Bt(2)cAMP) decreased TNF-alpha promoter activity. Bucladesine 82-96 tumor necrosis factor Homo sapiens 119-128 10750028-6 2000 Combination of forskolin or dibutyryl cAMP with TNFalpha produced a significantly greater increase in ET-2 production than these agents alone, indicating that adenylate cyclase and TNFalpha induce ET-2 synthesis by separate signalling pathways. Bucladesine 28-42 tumor necrosis factor Homo sapiens 181-189 10935448-5 2000 In contrast, beta-catenin protein levels were reduced markedly in NTera2-N cells by exposure to dbcAMP, EGF or bFGF, and in U-373MG cells by treatment with dbcAMP or PMA, but were unaffected in any cell lines by BDNF, TNF-alpha, IL-1beta, IL-6, IFN-gamma or TGF-beta1. Bucladesine 156-162 tumor necrosis factor Homo sapiens 218-227 10355595-2 1999 Pretreatment of neutrophils with dibutyryl cyclic AMP (dbcAMP) suppressed the TNF-alpha/cycloheximide-induced apoptosis in neutrophils in a concentration-dependent manner, while dbcAMP by itself did not induce any morphological changes. Bucladesine 33-53 tumor necrosis factor Homo sapiens 78-87 10355595-2 1999 Pretreatment of neutrophils with dibutyryl cyclic AMP (dbcAMP) suppressed the TNF-alpha/cycloheximide-induced apoptosis in neutrophils in a concentration-dependent manner, while dbcAMP by itself did not induce any morphological changes. Bucladesine 55-61 tumor necrosis factor Homo sapiens 78-87 10355595-2 1999 Pretreatment of neutrophils with dibutyryl cyclic AMP (dbcAMP) suppressed the TNF-alpha/cycloheximide-induced apoptosis in neutrophils in a concentration-dependent manner, while dbcAMP by itself did not induce any morphological changes. Bucladesine 178-184 tumor necrosis factor Homo sapiens 78-87 10355595-5 1999 DbcAMP also inhibited the TNF-alpha/cycloheximide-induced activation of caspase-3, but it had no effect on the activation of caspase-8 in human neutrophils. Bucladesine 0-6 tumor necrosis factor Homo sapiens 26-35 9877451-7 1998 Additional studies with PMA-treated human whole blood cultures confirmed that pentoxifylline, db-cAMP, and adenosine reduced TNF-alpha production by leukocytes. Bucladesine 94-101 tumor necrosis factor Homo sapiens 125-134 9877451-3 1998 TNF-alpha production in IL-1beta-stimulated or PMA-stimulated hepatocyte cultures was not altered following the addition of dihydrocortisone (< or = 1 microg/ml), dibutyryl-cAMP (db-cAMP, < or = 100 micromol/l), adenosine (< or = 1 mmol/l), thalidomide (< or = 25 microg/ml), or cyclosporine (< or = 300 ng/ml). Bucladesine 182-189 tumor necrosis factor Homo sapiens 0-9 10587479-2 1999 DC released tumour necrosis factor-alpha (TNF) in response to lipopolysaccharide (LPS) challenge, which was abolished both by dexamethasone and the cyclic AMP-elevating drugs db-cAMP and PGE(2). Bucladesine 175-182 tumor necrosis factor Homo sapiens 42-45 9038216-9 1997 Conversely, the cAMP analog dibutyryl cAMP (Bt2cAMP) blocked SNAP-induced TNF production (p = 0.001). Bucladesine 44-51 tumor necrosis factor Homo sapiens 74-77 9154331-11 1997 Both populations of cells were equally susceptible towards inhibition of TNF release by cyclic AMP elevating agents such as dibutyryl cyclic AMP, prostaglandin E2 (PGE2) or forskolin, which all led to a complete abrogation of TNF production in a concentration-dependent manner and which were more efficient than the glucocorticoid dexamethasone. Bucladesine 124-144 tumor necrosis factor Homo sapiens 73-76 9154331-11 1997 Both populations of cells were equally susceptible towards inhibition of TNF release by cyclic AMP elevating agents such as dibutyryl cyclic AMP, prostaglandin E2 (PGE2) or forskolin, which all led to a complete abrogation of TNF production in a concentration-dependent manner and which were more efficient than the glucocorticoid dexamethasone. Bucladesine 124-144 tumor necrosis factor Homo sapiens 226-229 9573235-6 1998 Addition of dibutyryl-cyclic AMP (dBcAMP) mimicked the effects of rolipram on p24 antigen release, NF-kappaB activation, and TNF-alpha secretion, but it did not affect NFAT activation or IL-10 production. Bucladesine 12-32 tumor necrosis factor Homo sapiens 125-134 9573235-6 1998 Addition of dibutyryl-cyclic AMP (dBcAMP) mimicked the effects of rolipram on p24 antigen release, NF-kappaB activation, and TNF-alpha secretion, but it did not affect NFAT activation or IL-10 production. Bucladesine 34-40 tumor necrosis factor Homo sapiens 125-134 9352314-8 1997 Increasing concentrations of dbcAMP progressively reduced the production of TNF-alpha and IL-1 beta but not IL-8. Bucladesine 29-35 tumor necrosis factor Homo sapiens 76-85 9127437-4 1997 Dibutyryl cyclic AMP (dbcAMP) also inhibited the production of TNF-alpha and IL-1 beta, but not IL-8. Bucladesine 0-20 tumor necrosis factor Homo sapiens 63-72 9127437-4 1997 Dibutyryl cyclic AMP (dbcAMP) also inhibited the production of TNF-alpha and IL-1 beta, but not IL-8. Bucladesine 22-28 tumor necrosis factor Homo sapiens 63-72 9127437-5 1997 TNF-alpha production was almost completely inhibited by dbcAMP, whereas IL-1 beta production appeared to be partially refractory even at the highest concentration examined. Bucladesine 56-62 tumor necrosis factor Homo sapiens 0-9 8702838-3 1996 Both forskolin and dibutyryl cAMP, which elevate intracellular cAMP by independent mechanisms, inhibited TNFalpha and tissue factor expression at the level of transcription. Bucladesine 19-33 tumor necrosis factor Homo sapiens 105-113 8781564-8 1996 However, coincubation of mesangial cells with TNF-alpha and either dbcAMP, forskolin, or pertussis toxin inhibited TNF-alpha-induced M-CSF gene expression. Bucladesine 67-73 tumor necrosis factor Homo sapiens 115-124 18475747-0 1996 Phosphodiesterase 4 inhibitors and db-cAMP inhibit TNF-alpha release from human mononuclear cells. Bucladesine 35-42 tumor necrosis factor Homo sapiens 51-60 8925408-8 1996 Furthermore, adenylate cyclase activation with prostaglandin E2 or dibutyryl cyclic AMP, inhibited exocytosis in response to TNF alpha and FMLP, while having no effect on the release induced by vanadate or PMA. Bucladesine 67-87 tumor necrosis factor Homo sapiens 125-134 18475747-6 1996 The present data indicate that db-cAMP inhibits TNF-alpha release from human mononuclear cells through a PKA-dependent mechanism. Bucladesine 31-38 tumor necrosis factor Homo sapiens 48-57 7547677-7 1995 Paradoxically, drugs that effectively inhibit expression of TNF-alpha via the elevation of intracellular cAMP level (iloprost, pentoxifylline, prostaglandin E2 and N6,2-O-dibutyryl cAMP) augmented the endotoxin-induced IL-10 synthesis at both protein and mRNA levels. Bucladesine 164-185 tumor necrosis factor Homo sapiens 60-69 7601571-0 1995 Expression of type A and B tumor necrosis factor (TNF) receptors on melanoma cells can be regulated by dbc-AMP and IFN gamma. Bucladesine 103-110 tumor necrosis factor Homo sapiens 50-53 7601571-9 1995 Treatment of cultured melanoma cells with dbc-AMP resulted in a selective induction of type-A TNF-receptors, without affecting the type-B receptor level. Bucladesine 42-49 tumor necrosis factor Homo sapiens 94-97 8181903-4 1994 Treatment of the Fc gamma RI+ Mphi with db cAMP decreases both their expression of CD64 and their capacity to produce TNF alpha to the levels typical of Fc gamma RI- Mphi. Bucladesine 40-47 tumor necrosis factor Homo sapiens 118-127 8138241-11 1994 Dibutyryl cyclic AMP, prostaglandin E1, prostaglandin E2 and the adenosine A2-receptor agonist N-ethylcarboxyamideadenosine inhibited lipopolysaccharide-stimulated tumor necrosis factor-alpha release by 83%, 97%, 90% and 94%, respectively, but inhibited peptidoglycan-polysaccharide-stimulated tumor necrosis factor-alpha release by 52%, 60%, 45% and 51%, respectively (p < 0.001 for each). Bucladesine 0-20 tumor necrosis factor Homo sapiens 164-191 8138241-11 1994 Dibutyryl cyclic AMP, prostaglandin E1, prostaglandin E2 and the adenosine A2-receptor agonist N-ethylcarboxyamideadenosine inhibited lipopolysaccharide-stimulated tumor necrosis factor-alpha release by 83%, 97%, 90% and 94%, respectively, but inhibited peptidoglycan-polysaccharide-stimulated tumor necrosis factor-alpha release by 52%, 60%, 45% and 51%, respectively (p < 0.001 for each). Bucladesine 0-20 tumor necrosis factor Homo sapiens 294-321 8230718-0 1993 [Effects of DbcAMP on tumor necrosis factor and interleukin-1 production in human monocytes]. Bucladesine 12-18 tumor necrosis factor Homo sapiens 22-43 7511557-2 1993 Similar to what is observed in normal conditions, treatment of immortal microglial cell lines with dibutyryl-cAMP blocked the accumulation of TNF alpha transcripts induced by lipopolysaccharide, whereas activation of Interleukin-1 alpha (IL-1 alpha) remained unaffected. Bucladesine 99-113 tumor necrosis factor Homo sapiens 142-151 8230718-2 1993 To determine whether DbcAMP suppresses the production of tumor necrosis factor (TNF) and interleukin-1 (IL-1) in human monocytes, we measured the levels of TNF and IL-1 in response to E. Coli lipopolysaccharide (40 micrograms.ml-1) in vitro. Bucladesine 21-27 tumor necrosis factor Homo sapiens 57-78 8230718-2 1993 To determine whether DbcAMP suppresses the production of tumor necrosis factor (TNF) and interleukin-1 (IL-1) in human monocytes, we measured the levels of TNF and IL-1 in response to E. Coli lipopolysaccharide (40 micrograms.ml-1) in vitro. Bucladesine 21-27 tumor necrosis factor Homo sapiens 80-83 8230718-3 1993 We now show that DbcAMP suppressed dose-dependently the production of TNF in human monocytes, and DbcAMP totally suppressed it at the dose above 5 x 10(-4) M. However, DbcAMP did not suppress the production of IL-1 even at the dose of 5 x 10(-3) M in human monocytes. Bucladesine 17-23 tumor necrosis factor Homo sapiens 70-73 2156930-11 1990 Moreover, the cyclooxygenase metabolite, PGE2, as well as dibutyryl cAMP, inhibited the induction of TNF transcripts by LPS. Bucladesine 58-72 tumor necrosis factor Homo sapiens 101-104 7688579-0 1993 Regulation of two forms of the TNF receptors by phorbol ester and dibutyryl cyclic adenosine 3",5"-monophosphate in human histiocytic lymphoma cell line U-937. Bucladesine 66-112 tumor necrosis factor Homo sapiens 31-34 1848573-5 1991 Suppression of chloramphenicol acetyltransferase and TNF mRNA synthesis, observed after treatment of the macrophages with dexamethasone, 2-aminopurine, pentoxifylline, or dibutyryl cAMP, has also been studied in detail. Bucladesine 171-185 tumor necrosis factor Homo sapiens 53-56 35410356-5 2022 Similarly, dbcAMP partially inhibited TNFalpha-induced MMP-3 release. Bucladesine 11-17 tumor necrosis factor Homo sapiens 38-46 2460096-5 1988 Furthermore, additional methylxanthines and dibutyryl cAMP have similar effects on TNF expression. Bucladesine 44-58 tumor necrosis factor Homo sapiens 83-86 33552397-20 2021 A cell-permeable cAMP analog, dibutyryl cAMP, inhibited both LPS-induced MMP-9 and TNFalpha secretion. Bucladesine 30-44 tumor necrosis factor Homo sapiens 83-91